In vitro validation of 99mTc-HFA-FP delivered via pMDI-spacer

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 19, Issue 3, 2006, Pages 254-260

  Roller, Christina M ^a,b   Schaefer, Nicole C ^a   Zhang, Guicheng ^a   Devadason, Sunalene G ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

Author keywords

Fine particle fraction; Fluticasone propionate; Particle size distribution; Pressurized metered dose inhaler; Radiolabel; Spacer; Technetium 99m; Validation

Indexed keywords

ANTIASTHMATIC AGENT; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; PROPELLANT; TECHNETIUM 99M; ALKANONE; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; FLUTICASONE; PERTECHNETIC ACID TC 99M; TECHNETIUM;

ASTHMA; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG LABELING; IONIZATION CHAMBER; METERED DOSE INHALER; PARTICLE SIZE; ULTRAVIOLET SPECTROPHOTOMETRY; ARTICLE; CHEMISTRY; IN VITRO STUDY; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER;

ADMINISTRATION, INHALATION; AEROSOL PROPELLANTS; ANDROSTADIENES; BRONCHODILATOR AGENTS; BUTANONES; DRUG DELIVERY SYSTEMS; METERED DOSE INHALERS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; SODIUM PERTECHNETATE TC 99M; TECHNETIUM;

EID: 33750963807     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2006.19.254     Document Type: Conference Paper

References (24)

1. Masoli, M.W., S. Holt, and R. Beasley. 2004. Systematic review of the dose response relation of inhaled fluticasone propionate. Arch. Dis. Child. 89:902-907.
2. Farr, S.J. 1996. The physico-chemical basis of radiolabelling metered dose inhalers with 99mTc. J. Aerosol Med. 9:S27-S35.
3. Dolovich, M. 1996. Standards for in vitro/in vivo measurements of MDIs. J. Aerosol Med. 9:S1-S2.
4. Snell, N.J., and D. Ganderton. 1999. Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British 1999. Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998. Respir. Med. 93:123-133.
5. Devadason, S.G., J.H. Wildhaber, J.M. Linto, et al. 1996. Factors affecting in vitro delivery from plastic spacers. Am. J. Respir. Crit. Care Med. 153:A60.
6. Pierart, F., J.H. Wildhaber, I. Vrancken, et al. 1999. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur. Respir. J. 13:673-678.
7. Wildhaber, J.H., S.G. Devadason, E. Eber, et al. 1996. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax 51:985-988.
8. Wildhaber, J.H., H.M. Janssens, F. Pierart, et al. 2000. High-percentage lung delivery in children from detergent-treated spacers. Pediatr. Pulmonol. 29:389-393.
9. Kohler, D., W. Fleischer, and H. Matthys. 1988. A new method for easy labeling of beta-2 agonists in the metered dose inhaler with Tc-99m. Respiration 53:65-73.
10. Newman, S.P., A.R. Clark, and N. Talaee. 1989. Pressurised aerosol deposition in the human lung with and without an "open" spacer device. Thorax 44:706-710.
11. Summers, Q.A., A.R. Clark, A. Hollingworth, et al. 1990. The preparation of a radiolabeled aerosol of nedocromil sodium for administration by metered dose inhaler that accurately preserves particle size distribution of the drug. Drug Invest. 2:90-98.
12. Clarke, J.G., S.J. Farr, and S.R. Wicks. 1992. Technetium-99m labelling of suspension type metered dose inhalers comprising various drug/surfactant combinations. Int. J. Pharm. 80:R1-R5.
13. Hardy, J.G., M. Everard, M. Coffiner, et al. 1993. Lung deposition of a Nacystelyn metered dose inhaler formulation. J. Aerosol Med. 6:37-44.
14. Newman, S.P. 1996. Characteristics of radiolabeled versus unlabeled inhaler formulations. J. Aerosol Med. 9:S37-S47.
15. Clark, A.R. 1996. MDIs: physics of aerosol formation. J. Aerosol Med. 9:S19-S26.
16. Dolovich, M. 1996. In vitro measurements of delivery of medications from MDIs and spacer devices. J. Aerosol Med. 9:S49-S58.
17. Leach, C. 1998. Targeting inhaled steroids. Int. J. Clin. Pract. Suppl. 96:23-27.
18. Leach, C. 1999. Effect of formulation parameters on hydrofluoroalkane- beclomethasone dipropionate drug deposition in humans. J. Allergy Clin. Immunol. 104:5250-5252.
19. Hammermaier, A., M. Bidlingmaier, J. Waitzinger, et al. 1994. Radio labeling of drugs in a metered dose inhaler (MDI) and lung deposition in human subjects. J. Aerosol Med. 7:173-176.
20. 99mTc-HFA-BDP inhaled via Autohaler in children. Eur. Respir. J. 21:1-5.
21. Melchor, R., M.F. Biddiscombe, V.H.F. Mak, et al. 1993. Lung deposition patterns of directly labeled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 48:506-511.
22. Warren, S., G. Taylor, J. Smith, et al. 2002. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique. J. Aerosol Med. 15:15-25.
23. Walker, P.S., G.L. Petterson, E. Bondesson, et al. 2001. An advanced and detailed in vitro validation procedure for the radiolabeling of carrier-free terbutaline sulphate dry powder. J. Aerosol Med. 14:227-236.
24. Dolovich, M.B., R.C. Ahrens, D.R. Hess, et al. 2005. Device selection and outcomes of aerosol therapy: evidence-based guidelines. American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 127:335-371.